|
|||||
|
|
Docetaxel in advanced renal carcinoma: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group |
|
| Authors: | Mertens, W. C. Eisenhauer, E. A. Jolivet, J. Ernst, S. Moore, M. Muldal, A. |
| Affiliation: | 1London Regional Cancer Centre London 2NCIC-Clinical Trials Group Kingston 3Hôpital Notre-Dame Montreal 4Tom Baker Cancer Centre Calgary 5Princess Margaret Hospital Toronto, Canada |
| Abstract: | BACKGROUND: Most patients diagnosed with renal carcinoma developed metastaticdisease at some time during their course, with available therapyinducing response in only a small proportion of patients. Docetaxel(Taxotere®, RP56976) a semisynthetic analogue of paclitaxelwith a broad range of in vitro antitumor activity, was evaluatedin a phase II study. METHODS: Eligibility criteria included histologically proven metastaticor advanced, bidimensionally measurable disease, no prior chemotherapy,immunotherapy, or hormonal therapy, adequate hematologic (neutrophils |
| Keywords: | |
| 本文献已被 Oxford 等数据库收录！ | |